- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00173862
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
A Phase II Study of Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced Transitional Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cisplatin-based combination chemotherapy produces a response rate of 40-70% in TCC patients. However, only less than 10% of the patients can achieve long-term remission. Until now, there is no standard chemotherapy for cisplatin-failed TCC patients. Both gemcitabine and ifosfamide have been identified to have response rates of 20% or more in pretreated TCC patients. It is thus reasonable to combine these two active drugs as a second-line treatment for TCC.
Patients enrolled must have a pathologically proven urothelial transitional cell carcinoma (TCC) and must have exposed to one cisplatin-based combination chemotherapy for the advanced disease. GI regimen will be continued until maximal response.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Department of Oncology , National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed transitional cell carcinoma
- Advanced / metastatic disease failed to prior chemotherapy (diagnostically confirmed disease progression during the treatment of last chemotherapy or within 6 months after the end of last chemotherapy)
- Presence of at least one measurable disease which is defined as lesion that can be measured in at least 1 dimension as ³ 20 mm with conventional technique or ³ 10 mm with spiral CT scan
- Performance status of ECOG 0, 1, 2
- Age 20 years or older
- Life expectancy more than 3 months
Adequate hematopoietic function as defined below:
- WBC ³ 3,000/uL
- Platelets ³ 75,000/Ul
Adequate organ function as defined below:
- Total bilirubin £ 1.5 ´ ULN
- ALT / AST£ 5 ´ ULN
- Creatinine £ 1.5 mg/dL
Adequate serum electrolyte concentration:
- 4 mmol/L<[K+] <5.3 mmol/L
- 0.74 mmol/L<[Mg2+] <1.03 mmol/
- 2.02 mmol/L<[Ca2+]<2.60 mmol/L
- Result of ECG assessment: QTC < 460 msec
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Received chemotherapy, radiotherapy, surgery, or other investigational drug within 4weeks prior to entering the study
- Receiving other concurrent palliative chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period
- Presence of CNS metastasis
- Previous or current malignancy with the exception of curatively treated non- melanoma skin cancer or cervical carcinoma in situ
Presence of serious concomitant illness which might be aggravated by study medication:
- Uncontrolled infection (active serious infections that are not controlled by antibiotics)
- Peripheral neuropathy grade 2 or higher (by NCI common toxicity criteria in sensory or motor neuropathy)
- Clinically significant arrhythmia (electrocardiogram QTc greater than 500 msec)
- Prior myocardial infarction or serious coronary arterial disease within the last 12 months
- Mental status is not fit for clinical trial.
- Women of child-bearing potential (pregnancy or breast feeding)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate
Time Frame: 2000~2006
|
2000~2006
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival, Safety
Time Frame: 2000~2006
|
2000~2006
|
Collaborators and Investigators
Investigators
- Study Chair: Ann-Lii Cheng, M.D., Ph.D., Department of Oncology, National Taiwan University Hospital
- Principal Investigator: Chih-Hung Hsu, M.D., Ph.D., Department of Oncology , National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Carcinoma, Transitional Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Gemcitabine
- Ifosfamide
Other Study ID Numbers
- 155I1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transitional Cell Carcinoma
-
Cliniques universitaires Saint-Luc- Université...NovartisTerminatedCarcinoma Transitional CellBelgium, Luxembourg
-
Associació per a la Recerca Oncologica, SpainUnknownUrothelium Transitional Cell CarcinomaSpain, Netherlands
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingTransitional Cell Carcinoma | Metastatic Urothelial Carcinoma | Unresectable Transitional Cell CarcinomaUnited States
-
UroGen Pharma Ltd.CompletedCarcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal PelvisUnited States, Israel
-
Memorial Sloan Kettering Cancer CenterNovartisCompletedMetastatic Transitional Cell Carcinoma of the UrotheliumUnited States
-
Institute of Cancer Research, United KingdomCancer Research UKUnknownTransitional Cell Carcinoma of UreterUnited Kingdom
-
Shaheen AlaneeMerck Sharp & Dohme LLCUnknownEndoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial CellsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedTransitional Cell Carcinoma of Urinary TractNetherlands
-
Yale UniversityWithdrawnTransitional Cell CarcinomaUnited States
-
Chinese PLA General HospitalCompleted
Clinical Trials on Gemcitabine, Ifosfamide
-
European Lung Cancer Working PartyCompletedCarcinoma, Non-Small-Cell LungBelgium, France, Greece, Spain
-
Gustave Roussy, Cancer Campus, Grand ParisUnknown
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma | Hodgkin's DiseaseAustralia
-
Antengene CorporationRecruitingPeripheral T-cell Lymphoma | NK/T-cell LymphomaChina
-
Italian Sarcoma GroupTerminated
-
Bayside HealthCompletedNon-Hodgkin's Lymphoma (CD20+)Australia
-
University of Michigan Rogel Cancer CenterCompletedSarcoma, Soft TissueUnited States
-
Tulane University Health Sciences CenterCompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and UreterUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral CancerUnited States
-
Istituto Clinico HumanitasCompleted